The company discovered and developed a novel protein drug discovery platform that targets integrin receptors activated in primary tumors, newly growing angiogenic vasculature, and metastatic foci. The platform enables rational drug design to create recombinant proteins that selectively target integrin receptors.The platform produced multiple novel recombinant proteins created and designed from a class of human proteins. Because integrin modulation is involved in many disease states the company foresees its novel platform will produce many novel drug candidates for many disease states and applications.
Vicrostatin is the Company's first recombinant protein drug candidate, derived from a naturally occurring non-human protein. ADM01, the first of twenty-three ADAM-Derived Disintegrin recombinant proteins discovered and developed from a family of human proteins, produces anti-cancer effects similar to Vicrostatin with additional attributes.
Both candidates engage the selected repertoire of integrin receptors involved in tumor growth, progression, and metastasis and demonstrate conserved pan-specificity yielding their anti-cancer effects. The novel mechanism of action induces a signaling cascade that produces the observed therapeutics effects.